Omics-imaging signature-based nomogram to predict the progression-free survival of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

Table 1 Clinical and imaging data features and univariate and multivariate analyses

Characteristics	Train cohort (n = 163)	P value	Test cohort (n = 38)	P value	Univariate analysis		Multivariate analysis
					OR	P value	OR	P value
Age	58.82 ± 10.36	0.178	57.76 ± 10.56	0.489	1.004	0.205
PIVKA	152.98 ± 182.31	0.191	112.56 ± 129.18	0.128	1	0.577
AST	105.43 ± 120.89	0.842	74.66 ± 65.83	0.572	0.999	0.027	1	0.684
ALT	45.54 ± 59.10	0.211	50.20 ± 38.58	0.093	0.999	0.287
GGT	82.91 ± 84.65	0.166	99.26 ± 71.53	0.087	1	0.333
AFP	68.05 ± 100.64	0.239	105.27 ± 102.15	0.014	0.999	0.005	1	0.187
Platelet	143.44 ± 80.10	0.554	153.53 ± 112.02	0.153	1	0.907
Tumor diameter	7.25 ± 4.08	< 0.001	7.44 ± 3.84	0.001	0.947	0.001	0.94	0.001
Gender		0.386		0.772	0.956	0.546
Female	38 (23.31)		13 (34.21)
Male	125 (76.69)		25 (65.79)
Hepatitis		0.866		0.542	0.954	0.468
No	88 (53.99)		17 (44.74)
Yes	75 (46.01)		21 (55.26)
Diolame		0.012		0.049	1.267	0.001	1.233	0.001
No	51 (31.29)		18 (47.37)
Yes	112 (68.71)		20 (52.63)
Metastasis		0.461		0.078	0.889	0.082
No	103 (63.19)		25 (65.79)
Yes	60 (36.81)		13 (34.21)
Necrosis		0.081		0.542	0.869	0.032	1.101	0.14
No	90 (55.21)		17 (44.74)
Yes	73 (44.79)		21 (55.26)
PVTT		0.283		0.333	0.895	0.095
No	106 (65.03)		12 (31.58)
Yes	57 (34.97)		26 (68.42)
Ascites		0.068		0.175	0.816	0.014	0.954	0.538
No	127 (77.91)		36 (94.74)
Yes	36 (22.09)		2 (5.26)
Regular		0.299		0.127	1.134	0.056
No	70 (42.94)		20 (52.63)
Yes	93 (57.06)		18 (47.37)
BCLC Stage		0.088		0.081	0.842	0.009	1.095	0.181
A stage	96 (58.90)		19 (50.00)
B stage	67 (41.10)		19 (50.00)

OR: Odds ratio; PIVKA: Protein Induced by vitamin k absence or antagonist; PVTT: Portal vein tumor thrombus; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: γ-glutamyltranspeptadas.